PMXSF Stock - Pharmaxis Ltd
Unlock GoAI Insights for PMXSF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $8.63M | $6.74M | $17.00M |
| Gross Profit | $-146,640 | $-154,651 | $-1,954,044 | $-4,549,991.88 | $5.42M |
| Gross Margin | N/A | N/A | -22.6% | -67.5% | 31.8% |
| Operating Income | $-19,874,000 | $-19,490,000 | $-11,704,950 | $-13,737,608.18 | $-3,304,054.054 |
| Net Income | $-7,919,000 | $-15,142,000 | $-7,565,760 | $-1,335,878.72 | $-2,229,729.73 |
| Net Margin | N/A | N/A | -87.7% | -19.8% | -13.1% |
| EPS | $-0.00 | $-0.01 | $-0.01 | $-0.00 | $-0.01 |
Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol Respiratory Business and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of oral pan-lysyl oxidase inhibitors (LOX) targeting myelofibrosis and other cancers; topical pan-LOX inhibitors targeting skin scarring after events, such as accidents, surgery,and burns; selective Lysyl Oxidase Like Inhibitors (LOXL2) targeting chronic fibrotic diseases, including kidney fibrosis, pulmonary fibrosis, liver fibrosis, and cardiac fibrosis; and semicarbazide-sensitive amine oxidase for neuro inflammatory diseases. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.
Visit WebsiteEarnings History & Surprises
PMXSFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 28, 2025 | — | — | — | — |
Q1 2025 | Feb 26, 2025 | — | $-0.00 | — | — |
Q3 2024 | Jul 30, 2024 | — | — | — | — |
Q1 2024 | Jan 30, 2024 | — | $-0.00 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.01 | — | — |
Q4 2022 | Dec 30, 2022 | — | $-0.01 | — | — |
Q3 2022 | Aug 30, 2022 | — | — | — | — |
Q3 2022 | Aug 30, 2022 | — | — | — | — |
Q1 2022 | Feb 10, 2022 | — | $-0.00 | — | — |
Q3 2021 | Aug 11, 2021 | — | — | — | — |
Q1 2021 | Feb 10, 2021 | — | — | — | — |
Q3 2020 | Aug 12, 2020 | $-0.02 | — | — | — |
Q1 2020 | Feb 12, 2020 | $-0.02 | $-0.00 | +98.8% | ✓ BEAT |
Q3 2019 | Aug 14, 2019 | — | — | — | — |
Q1 2019 | Jan 29, 2019 | — | — | — | — |
Q4 2018 | Oct 25, 2018 | — | — | — | — |
Q3 2018 | Aug 16, 2018 | — | — | — | — |
Q2 2018 | Apr 30, 2018 | — | — | — | — |
Q1 2018 | Feb 14, 2018 | — | — | — | — |
Q4 2017 | Oct 11, 2017 | — | — | — | — |
Latest News
Frequently Asked Questions about PMXSF
What is PMXSF's current stock price?
What is the analyst price target for PMXSF?
What sector is Pharmaxis Ltd in?
What is PMXSF's market cap?
Does PMXSF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to PMXSF for comparison